Breast care (Basel, Switzerland). 2019 Sep 17. doi: 10.1159/000502603. pii: brc-0014-0315. pmc: PMC6883436 |
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). |
Lüftner D1, Bauerfeind I2, Braun M3, Brucker SY4, Fasching PA5, Felberbaum R6, Hagemann F7, Haidinger R8, Harbeck N9, Hönig A10, Huober J11, Jackisch C12, Kolberg HC13, Kolberg-Liedtke C14, Kühn T15, Maass N16, Reimer T17, Schneeweiss A18, Schumacher-Wulf E19, Schütz F20, Thomssen C21, Untch M22, Wuerstlein R23, Thill M24 |
Abstract A German working group of leading breast cancer experts have discussed the votes at the International St. Gallen Consensus Conference in Vienna for the treatment of primary breast cancer with regard to the German AGO (Ar-beitsgemeinschaft Gynäkologische Onkologie) recommendations for clinical practice in Germany. Three of the German breast cancer experts were also members of this year's St. Gallen panel. Comparing the St. Gallen recommendations with the annually updated treatment recommendations of the Gynecological Oncology Working Group (AGO Mamma 2019) and the German S3 Guideline is useful, because the recommendations of the St. Gallen panel are based on expert opinions of different countries and disciplines. The focus of this article is on systemic therapy. The motto of this year's 16th St. Gallen Consensus Conference was "Estimating the magnitude of clinical benefit." The rationale behind this motto is that, for every treatment decision, a benefit-risk assessment must be taken into consideration for each patient. |
Copyright © 2019 by S. Karger AG, Basel. |
KEYWORDS: Axilla, Early breast cancer, Locoregional therapy, Neoadjuvant treatment, St. Gallen Consensus Conference 2019, Systemic therapy |
Publikations ID: 31798392 Quelle: öffnen |